Medicare tasks a senior adviser with staffing its new drug pricing division – STAT

Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Rachel Cohrs Oct. 6, 2022
WASHINGTON — Medicare has tasked a senior adviser at the agency with assembling a small army of bureaucrats to get its new drug price negotiation program up and running.
There are no job listings up on the federal government’s hiring website yet, but Medicare officials are already getting started with recruiting candidates. An organizational chart first obtained by STAT shows that the agency is aiming to hire 95 full-time employees.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Washington Correspondent
Rachel reports on the intersection of politics and health policy.






This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need

source

Add a Comment

Your email address will not be published. Required fields are marked *